Cancer clinical trials in the region Nouvelle-Aquitaine

381 currently recruiting clinical trials
Region Nouvelle-Aquitaine

Phase 3 Lung cancer #NCT06890598 #2024-512302-25-00
NSCLC (Non-Small Cell Lung Cancer) Localized Locally Advanced KRAS G12C PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Surgery Immunotherapy Chemotherapy
ALK EGFR
14 recruiting sites
Eli Lilly et compagnie
Phase 3 Breast cancer #NCT05633654
HER2 Negative HR Negative Localized Locally Advanced None Surgery Chemotherapy Radiotherapy Surgery Chemotherapy Radiotherapy
BRCA 1/2 Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC) Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
14 recruiting sites
Gilead Sciences
Phase 3 Lung cancer #NCT06801834 #2024-515884-69-00
SCLC (Small Cell Lung Cancer) Locally Advanced Metastatic 1 Chemotherapy
Systemic Treatment-Naive
12 recruiting sites
Gilead Sciences
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT03534713
Cervical cancer Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma Stage I Stage II Stage III Stage IV Localized Locally Advanced None Systemic Treatment-Naive Systemic Treatment-Naive
Chemotherapy Chemotherapy
11 recruiting sites
Hôpital universitaire de Toulouse
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05581121
Cervical cancer Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma Stage III Localized Locally Advanced None Systemic Treatment-Naive Systemic Treatment-Naive
Radiotherapy Radiotherapy
24 recruiting sites
Institut Claudius Regaud
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05078047
Cervical cancer Locally Advanced Metastatic
26 recruiting sites
UNICANCER
Phase 3 Head and neck cancer #NCT04892173
Oral cavity Oropharynx Hypopharynx Larynx Squamous cell carcinoma Locally Advanced None Systemic Treatment-Naive
Surgery Chemotherapy Radiotherapy Radiochemotherapy
15 recruiting sites
Johnson & Johnson Enterprise Innovation Inc.
Phase 3 Sarcoma and GIST #NCT07218926 #2025-522229-37-00
GIST Locally Advanced Metastatic 1 Targeted therapy
Systemic Treatment-Naive
5 recruiting sites
GlaxoSmithKline
Phase 3 Penile cancer and germ cell tumors #NCT05874063 #2022-502426-41-00
Germ cell tumor None Systemic Treatment-Naive Systemic Treatment-Naive Good prognosis Intermediate prognosis
18 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris